Catalog No.: PC-60934Not For Human Use, Lab Use Only.
HJC0152 is a potent, orally bioavailable STAT3 signaling inhibitor that exhibits promising antitumor effects in vitro and in vivo via inactivating STAT3 and downstream miR-21/β-catenin axis.
HJC0152 is a potent, orally bioavailable STAT3 signaling inhibitor that exhibits promising antitumor effects in vitro and in vivo via inactivating STAT3 and downstream miR-21/β-catenin axis.
HJC0152 potently inhibits MCF-7, MDA-MB-231, AsPC1 and Panc-1a cell with IC50 of 0.91, 1.64, 1.9 and 1.08 uM, respectively.
HJC0152 suppresses HNSCC cell proliferation, arrests the cell cycle at the G0-G1 phase, induces apoptosis and reduces cell invasion in both SCC25 and CAL27 cell lines.
HJC0152 inhibits nuclear translocation of phosphorylated STAT3 at Tyr705 and decreases VHL/β-catenin signaling activity via regulation of miR-21。
HJC0152 suppresses MDA-MB-231 xenograft tumor growth in vivo.
